Intranasal treatment of GHK-Cu [45] provokes a reduction in amyloid plaques and a decrease in monocyte chemoattractant protein-1 (MCP-1), a key mediator in AD inflammatory processes [222]. This evidence concerns the gene CCL2 and Alzheimer disease.